Prostate Cancer
Articles tagged with Prostate Cancer
Screening modestly reduces prostate cancer deaths
UT MD Anderson shares latest research breakthroughs
New marker aids diagnosis for aggressive prostate cancer
Bobba receives Young Investigator Award for prostate cancer research
Testosterone treatment improved sexual and physical function for men after prostate cancer surgery
A randomized clinical trial found that testosterone treatment significantly improved sexual activity, sexual desire, and quality of life scores in men after prostate cancer surgery. The treatment also improved body composition and aerobic performance without increasing the risk of biochemical recurrence.
City of Hope researchers to share new immunotherapy and precision medicine insights across cancer types at ASCO 2026
At ASCO 2026, City of Hope experts will present research on innovative treatments for various types of cancer. Their findings include the efficacy and safety of immunotherapy combinations, as well as the potential use of CBM588 to enhance immune checkpoint blockade in metastatic renal cell carcinoma.
Urine test better than MRI for monitoring low-risk prostate cancer in new study
ASCO 2026 Tip Sheet - Sylvester Comprehensive Cancer Center
Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.
Trial now enrolling seeks to answer key question: Does adding chemotherapy to hormone therapy improve survival for metastatic prostate cancer?
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
The benefits of prostate cancer screening outweigh the harms, according to new patient guidelines from NCCN
The new NCCN Guidelines for Patients: Prostate Cancer Screening provide a comprehensive guide to evidence-based recommendations for age-specific screening. The guidelines aim to balance the benefits of early detection with the risks of unnecessary procedures, emphasizing the importance of personalized care and monitoring.
Drugging the undruggable: Scientists achieve million-fold leap in targeting elusive cancer proteins
Researchers at the University of British Columbia have developed a new method to target intrinsically disordered proteins, which are difficult to treat with medication. The approach has shown promise in slowing prostate cancer growth and could lead to new treatments for various diseases.
Prostate cancer overdiagnosis rises sharply with age
A new study found that prostate cancer overdiagnosis increases with age, with low rates in younger men and high rates in older men. The study suggests that targeted PSA testing or screening policies for men in their 50s and early 60s may be more effective.
Federal housing assistance may lead to improved two-year survival among older people with prostate cancer
New research suggests that federal housing assistance may lead to better two-year survival chances among older men with prostate cancer. The study found a 12% lower risk of death in men who received housing assistance compared to those without it.
Epigenetic dysregulation of PDX1 drives prostate cancer progression
Research finds PDX1 gene plays a tumor-promoting role in human PCa cells by influencing metabolic pathways. The study identifies PDX1 as differentially hypermethylated in prostate cancer tissues, contributing to its aggressive characteristics.
New study shows faster recovery with minimally invasive prostate cancer treatment
A new randomized clinical trial found that men with localized, intermediate-risk prostate cancer recovered faster and experienced less short-term impact on their daily lives when treated with MRI-guided, transurethral ultrasound ablation (TULSA) compared to robotic prostate surgery. TULSA resulted in less blood loss, shorter hospital s...
EANM joins EMUC26 as co-organizer of Europe’s leading urological cancer congress
The European Association of Nuclear Medicine (EANM) has joined the EMUC26 congress to promote nuclear medicine expertise in urological cancers. The event will bring together healthcare professionals from various disciplines to discuss current practices and emerging innovations.
Scientists discover how key immune cells protect the prostate
Researchers reveal that immune system's T cells travel to the prostate to provide long-term protection against infections. Harnessing these disease-fighting cells could lead to new therapies for prostate cancer and inflammatory conditions.
Study: Diabetes drug, metformin, may echo the benefits of exercise in prostate cancer care
A new study found that metformin raises levels of N-lactoyl-phenylalanine, a molecule tied to energy balance and weight control, in men with prostate cancer. This finding suggests metformin could help counter metabolic strain caused by hormone therapy, which often limits physical activity.
First-in-class dual HIF inhibitors eliminate breast, colorectal, melanoma, and prostate tumors in mice when combined with immunotherapy
Researchers developed first-in-class dual HIF inhibitors that, when combined with immunotherapy, can completely eliminate breast, colorectal, melanoma, and prostate tumors in mice. The drugs target HIF-1/2 transcription factors, which are key regulators of cancer progression.
Innovative targeted therapy halts prostate cancer spread to the bone
Researchers at VCU Massey Comprehensive Cancer Center developed a targeted therapy that effectively prevents prostate tumors from spreading to the bone. The small molecule inhibitor IVMT-Rx-4 blocks the function of MDA-9/Syntenin, preventing tumor growth and improving survival in models with bone metastasis.
Targeting MD2 could limit prostate cancer bone metastasis
Researchers found that targeting MD2 could reduce tumor growth in a mouse model of prostate cancer bone metastasis. High MD2 expression was associated with metastasis, immune suppression, and increased resistance to PARP inhibitor therapy.
PSMA therapy delays hormone therapy in prostate cancer
A new study shows that PSMA therapy can delay the need for hormone therapy in prostate cancer patients by an average of 20 months. The therapy is effective in earlier stages of the disease, improving survival and quality of life for approximately two out of three patients.
Prostate Cancer Foundation awards grants to Weill Cornell Medicine investigators
Six Weill Cornell Medicine researchers have been awarded Young Investigator Awards by the Prostate Cancer Foundation to investigate prostate cancer at a molecular level and develop new therapies. Drs. Bashir Al Hussein Al Awamlh, Cheuk Man Cherie Au, Lise Brault, Xuanrong Chen, Kevin Kensler, and Silvia Rodrigues will focus on improvin...
Scalable platform sheds light on how cancer spreads
A new platform called ATLAS enables researchers to generate large quantities of cancer cell clusters that accurately model metastasis. Using ATLAS, the Rice team gained insights into the mechanisms that enable cancer clusters to survive in the bloodstream during the metastatic process.
Hormone patches effective for locally advanced prostate cancer
A large clinical trial led by UCL researchers has shown that hormone patches are as effective as injections in controlling locally advanced prostate cancer. The patches cause fewer side effects, including hot flushes and breast tissue swelling, while improving quality of life for men with the condition.
Cellular ‘atlas’ of prostate cancer opens new avenues for earlier detection
Scientists have identified a new cell type and discovered that many normal-looking prostate cells harbor cancer-related changes. The study's findings could lead to new risk factors, earlier detection methods, and more targeted therapies for patients at high risk of aggressive disease.
CREB5 linked to stem cell-like programs that promote prostate cancer progression
A study found CREB5 regulates basal and SCL transcriptional programs and tumor-forming phenotypes in prostate cancer, suggesting a central role in aggressive prostate cancer. Disrupting CREB5-regulated pathways may improve therapeutic responses in advanced disease.
Newly discovered genetic weakness may help target deadly small cell neuroendocrine cancers
UCLA researchers identified a key protein, E2F3, essential for survival in cancer cells lacking the protective gene RB. Blocking E2F3 effectively halted tumor growth, offering a new strategy for treating aggressive cancers.
Anil Parsram Bidkar, PhD, receives SNMMI-PCF Young Investigator's Award
Bidkar aims to develop a novel CD46-targeted radiotheranostic platform to treat metastatic castration-resistant prostate cancer. His proposal focuses on overcoming tumor heterogeneity and improving treatment outcomes.
Scientists “turbocharge” immune cells to attack prostate cancer
Researchers engineered supercharged T cells that can recognize and kill prostate cancer cells more effectively. By fine-tuning how they physically interact with tumor cells, the T cells form a stronger bond, allowing them to deliver a targeted immune response without damaging healthy tissue.
Prostate cancer screening as good as breast cancer screening, say researchers
Researchers compare prostate cancer screening to breast cancer screening, finding similarities in identifying significant cancers and reducing mortality. The study suggests that prostate cancer screening should be reconsidered, offering benefits over harms, and highlights the need for further analysis on costs.
Scan that makes prostate cancer cells glow could cut need for biopsies
A new imaging test, PSMA PET/CT scan, has been shown to safely reduce the number of biopsies needed for suspected prostate cancer, with no harm to patients. The PRIMARY2 trial found that the scan could identify low-risk patients who did not need a biopsy, while targeting suspicious areas for those who did.
Sylvester Cancer Tip Sheet for March 2026
The Sylvester Cancer Tip Sheet for March 2026 highlights the importance of genetic testing for cancer risk assessment. Researchers have made significant progress in developing new treatments, including mRNA-based immunotherapy for colorectal and pancreatic cancers. Additionally, the Dolphins Cancer Challenge has surpassed $100 million ...
Research presented at international urology conference in London shows how far prostate cancer screening has come
Research presented at EAU26 confirms that prostate cancer screening leads to a reduction in mortality, but also detects cancers that would otherwise remain undetected. The study's findings suggest that using MRI in prostate cancer screening can reduce overdiagnosis and unnecessary biopsies.
MYC amplification in metastatic prostate cancer associated with reduced tumor immunogenicity
A new study found that MYC amplification in metastatic prostate cancer is associated with reduced tumor immunogenicity, making it harder for the immune system to detect and attack the tumor. This reduction in immunogenicity was linked to poorer progression-free survival outcomes in patients with MYC-amplified tumors.
Low testosterone levels may be associated with increased risk of prostate cancer progression during surveillance
A study by the University of Texas M. D. Anderson Cancer Center found that men with low testosterone levels are 60% more likely to have their prostate cancer progress to a more aggressive state during surveillance. Low testosterone may serve as a useful clinical marker to guide treatment and surveillance strategies.
Study identifies gene linked to chemotherapy resistance in prostate cancer
Researchers at Weill Cornell Medicine have identified the FOXJ1 gene as a key player in chemotherapy resistance in prostate cancer. The study found that increased FOXJ1 levels in tumors can make cancer cells less responsive to taxane chemotherapy, leading to poorer outcomes for patients.
Do prostate cancer drugs interact with certain anticoagulants to increase bleeding and clotting risks?
A study of 2,997 adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and anticoagulants found no increased risks of bleeding or clotting. The findings contradict previous lab results and provide reassurance for clinicians and patients managing anticoagulation alongside modern prostate cancer treatments.
Weill Cornell Medicine selected for Prostate Cancer Foundation Challenge Award
Researchers at Weill Cornell Medicine will develop an AI system to identify patients with early signs of treatment-resistant prostate cancer. The project aims to improve clinical trials by predicting treatment outcomes and avoiding ineffective treatments for patients with specific tumor subtypes.
Study: Cancer’s clues in the bloodstream reveal the role androgen receptor alterations play in metastatic prostate cancer
Researchers found that tumors with androgen receptor alterations experienced poorer outcomes, shorter overall survival, and earlier need for subsequent therapy. Serial liquid biopsies revealed real-time molecular changes linked to treatment pressure.
Study identifies potential immunotherapy strategy for early-stage prostate cancer
Researchers developed a new immunotherapy strategy by pairing next-generation therapy with standard hormone therapy before surgery, reducing Treg levels inside tumors and improving patient outcomes. The study provides clinical evidence for the effectiveness of engineered anti-CTLA-4 therapies in early-stage prostate cancer treatment.
Hormone therapy may not benefit most men receiving radiotherapy after prostate surgery, UCLA study finds
A new UCLA study suggests that adding hormone therapy to post-operative radiotherapy may provide little survival benefit for most men with prostate cancer, especially those with low PSA levels. However, men with higher PSA levels before radiation may see modest improvements in survival and metastasis-free survival.
EANM launches new award to accelerate alpha radioligand therapy research
The European Association of Nuclear Medicine (EANM) has launched a new award to accelerate alpha radioligand therapy (α-RLT) research in prostate cancer. The EANM Young Scientist Network Award offers €40,000 in funding for promising researchers.
Microplastics discovered in prostate tumors
A new study has discovered microplastics in nine out of ten patients with prostate cancer, with higher levels found in tumor tissue than noncancerous tissue. The findings suggest that microplastic exposure may be a risk factor for prostate cancer.
Scientists report landmark “evolutionary double-bind” strategy to overcome treatment resistance in prostate cancer
Researchers found that radiation-resistant cancer cells are vulnerable to NK cell-mediated killing due to increased expression of specific cellular membrane proteins, creating an 'evolutionary double-bind'. The combination of radiation therapy and NK cell-based immunotherapy was more effective in suppressing both sensitive and resistan...
UH Seidman Cancer Center researchers find real world data can inform care for metastatic castration-resistant prostate cancer
Researchers found patients who retreated with docetaxel had longer overall survival and fewer supportive-care needs compared to those switching to cabazitaxel. The study provides evidence-based options for selected patients previously tolerated docetaxel.
Research highlights from the first Multidisciplinary Radiopharmaceutical Therapy Symposium
Studies presented at the inaugural Multidisciplinary Radiopharmaceutical Therapy Symposium highlight the growing potential of RPTs to improve cancer outcomes. A meta-analysis shows Lu-177 PSMA-617 consistently prolongs progression-free survival without adding severe side effects for patients with advanced prostate cancer.
New treatment works to improve hot flash symptoms in prostate cancer therapy
A medication commonly used to treat overactive bladder significantly reduced hot flashes in men receiving hormone therapy for prostate cancer. Men who took oxybutynin also reported improvements in day-to-day functioning and overall quality of life.
Focal therapy effectively treats men whose prostate cancer returns after radiotherapy with fewer side effects, says new study
Identified aggressive prostate cancer with groundbreaking methods
Researchers identified a gene expression signature and inflammation patterns in normal tissue near the tumor to distinguish between patients with aggressive disease. The study paves the way for early identification of high-risk patients through blood or semen samples.
New study in JNCCN unlocks important information about how to treat recurring prostate cancer
Researchers found that PSMA PET/CT scans can help guide treatment planning and improve long-term outcomes for patients with recurring prostate cancer. The study suggests that incorporating these scans into routine care may lead to better results and reduced side effects.
Decoding a new "engine" of prostate cancer—team led by professor Jun Pang from Department of Urology at the Seventh Affiliated Hospital of Sun Yat-Sen University unveils novel mechanism of CDK12-FOXA1 pathway driving progression
A new study reveals the CDK12-FOXA1-MDM2-p53 signaling axis promotes prostate cancer development through FOXA1 modification. The study identifies S234 phosphorylation as a critical site, and a CDK12 inhibitor THZ531 effectively blocks this pathway, reducing tumor growth.
Half of all men over 60 have prostate cancer – an AI diagnostic tool could identify which need followup
A new AI-powered analysis tool called PROVIZ is being tested in Norwegian hospitals to diagnose prostate cancer. The tool helps doctors determine which patients need a biopsy, reducing the number of unnecessary procedures.
Study shows strong evidence for effectiveness of metastasis-directed radiation therapy in prostate cancer
A meta-analysis of individual patients with oligometastatic prostate cancer shows that metastasis-directed radiation therapy (MDT) significantly improves patient outcomes, including delayed disease progression and better quality of life. The study included 574 men and found a median of 7.6 months before disease progression in the MDT a...
Randomized trial finds drug therapy reduces hot flashes during prostate cancer treatment
A national clinical trial found that oxybutynin significantly reduced hot flash frequency and quality of life for men undergoing hormone therapy for prostate cancer. The study showed substantial improvements in hot flash symptoms, often within the first week of treatment.
Chinese Medical Journal article review decodes GDF15 in prostate cancer metabolic character and therapies
A review decodes the comprehensive role of GDF15 in prostate cancer metabolism, chemoresistance, and clinical applications, highlighting its involvement in cachexia, bone metastasis, and drug resistance. The study also explores the synergistic power of combining GDF15 with established markers for improved diagnosis and prognosis.
New AI tool helps doctors treat cancer patients after heart attack
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
Novel laser therapy device generates promising results in prostate cancer clinical trial
A clinical trial has shown that a novel cooled laser focal therapy device can effectively treat prostate cancer with minimal side effects. The treatment provided similar cancer-related outcomes to traditional methods but with an improved safety profile and low rates of incontinence.
City of Hope opens clinical trial to protect heart health of prostate cancer patients receiving hormone therapy
A phase 2 clinical trial is comparing three strategies to protect heart health in prostate cancer patients undergoing hormone therapy. The study will assess the impact of intermittent fasting, GLP-1 medication, and nutritional counseling on cardiovascular and metabolic risks associated with androgen deprivation therapy.